<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2400BE3D-876A-41C9-8178-94887A51CA1C"><gtr:id>2400BE3D-876A-41C9-8178-94887A51CA1C</gtr:id><gtr:name>University Hospitals Birmingham NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Metchley Park Road</gtr:line1><gtr:city>Birmingham</gtr:city><gtr:postCode>B15 2PR</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3DF2F8DD-33A5-44A1-81D7-347A6C2FBDC8"><gtr:id>3DF2F8DD-33A5-44A1-81D7-347A6C2FBDC8</gtr:id><gtr:name>Stanford University</gtr:name><gtr:address><gtr:line1>450 Serra Mall</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C705F4C9-3E9D-4C2A-90B0-49C636E962EE"><gtr:id>C705F4C9-3E9D-4C2A-90B0-49C636E962EE</gtr:id><gtr:name>Barts Health NHS Trust</gtr:name><gtr:address><gtr:line1>9 Prescot Street
Aldgate</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>E1 8PR</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2400BE3D-876A-41C9-8178-94887A51CA1C"><gtr:id>2400BE3D-876A-41C9-8178-94887A51CA1C</gtr:id><gtr:name>University Hospitals Birmingham NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Metchley Park Road</gtr:line1><gtr:city>Birmingham</gtr:city><gtr:postCode>B15 2PR</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3DF2F8DD-33A5-44A1-81D7-347A6C2FBDC8"><gtr:id>3DF2F8DD-33A5-44A1-81D7-347A6C2FBDC8</gtr:id><gtr:name>Stanford University</gtr:name><gtr:address><gtr:line1>450 Serra Mall</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C705F4C9-3E9D-4C2A-90B0-49C636E962EE"><gtr:id>C705F4C9-3E9D-4C2A-90B0-49C636E962EE</gtr:id><gtr:name>Barts Health NHS Trust</gtr:name><gtr:address><gtr:line1>9 Prescot Street
Aldgate</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>E1 8PR</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7C77CA31-E4B1-49B0-B014-0CE3E7BA17D0"><gtr:id>7C77CA31-E4B1-49B0-B014-0CE3E7BA17D0</gtr:id><gtr:firstName>Paresh</gtr:firstName><gtr:surname>Vyas</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U137961146"><gtr:id>47A3FE16-9A7A-4BF3-90FF-27CEFD73426B</gtr:id><gtr:title>Transcriptional Regulation of GATA-1</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U137961146</gtr:grantReference><gtr:abstractText>A common cause of severe anaemia that can progress to leukaemia is known as myelodysplasia. In this condition blood cell precursors are made but fail to mature properly and do not function appropriately. Understanding this disorder depends on knowing how blood cells are normally made and mature in the bone marrow.||Our interest has focused on one critical factor that is required in this process, which is called GATA-1. GATA-1 co-ordinates many aspects of the normal maturation programme of blood and we wish to aspects of it biology.</gtr:abstractText><gtr:technicalSummary>A key biological question, relevant to all differentiating tissues, is how multiple cell types arise from a pluripotential cell. When this process is perturbed it leads to human disease. We are using the haemopoietic system to study this question as it provides a good scientific and clinical model. Our laboratory is focused on how the erythroid and megakaryocytic lineages are specified and mature from a progenitor cell. Our particular interest is the role key transcription factors play in these processes. In particular, the zinc-finger transcription factor GATA-1 is absolutely required for the proper maturation of both the red cell and megakaryocyte lineages. In addition, GATA-1 expression is initiated in early haematopoietic progenitor at low level but then is restricted to principally erythroid and megakaryocytic cells where it is expressed at high level.||Our aim is to understand the molecular mechanisms that result in the tissue- and developmental- specific pattern of expression. As a consequence of these studies we hope to identify the transcriptional regulators that lie upstream of GATA-1 and thus help to specify the erythroid and megakaryocyte lineages.||Our approach to this problem is to try and identify all the cis-acting elements that are required for GATA-1 expression and the trans-acting factors that bind to them. We are identifying putative cis-elements in the GATA-1 locus by DNase I hypersensitivity analysis and by pin-pointing non-coding sequence that is conserved in evolution between mouse and human. Once putative cis-elements have been identified we are testing if they have function in stable cell transfection assays and in transgenic mice. Protein-DNA interactions at functionally important elements will be then be determined. Lastly, the functional importance of selected elements will be further examined by deleting them by homologous recombination in mice.</gtr:technicalSummary><gtr:fund><gtr:end>2010-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2001-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>1682374</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals Birmingham NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Queen Elizabeth Medical Centre, Birmingham</gtr:department><gtr:description>Development of novel therapeutic anti-leuakemia stem cell antibodies</gtr:description><gtr:id>C213F413-20CC-4D83-8960-FA7FC03CF581</gtr:id><gtr:impact>Grants 2009 &amp;pound;2.2 M MRC Disease Team Award Publications (PubMed ID numbers below): 19664981 19546437 19644143</gtr:impact><gtr:outcomeId>B7E2966F68D-2</gtr:outcomeId><gtr:partnerContribution>It has provided access to novel technologies and unpublished dataAccess to novel therapies. Access to patient samples. Access to laboratory collaborations. Acquisition of biological samples and clinical data. Acquisition of biological samples and clinical data</gtr:partnerContribution><gtr:piContribution>We lead the UK component of this transatlantic collaboration. The basic science and translational studies are driven from Oxford.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Barts Health NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Haematology</gtr:department><gtr:description>Development of novel therapeutic anti-leuakemia stem cell antibodies</gtr:description><gtr:id>10BFD425-C0DD-49DD-A989-B5D2D32F53F1</gtr:id><gtr:impact>Grants 2009 &amp;pound;2.2 M MRC Disease Team Award Publications (PubMed ID numbers below): 19664981 19546437 19644143</gtr:impact><gtr:outcomeId>B7E2966F68D-4</gtr:outcomeId><gtr:partnerContribution>It has provided access to novel technologies and unpublished dataAccess to novel therapies. Access to patient samples. Access to laboratory collaborations. Acquisition of biological samples and clinical data. Acquisition of biological samples and clinical data</gtr:partnerContribution><gtr:piContribution>We lead the UK component of this transatlantic collaboration. The basic science and translational studies are driven from Oxford.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Haematology</gtr:department><gtr:description>Downs Syndrome associated preleukaemia and leukaemia</gtr:description><gtr:id>5309BCDC-6338-4E40-941B-0CD001074975</gtr:id><gtr:impact>Grants 2008 Leukaemia Research 5-year Programme Grant, &amp;pound;1.03 M Publications (PubMed ID below): 19594743 18242315 18689547 18059480 18625887 17804520 17644747 17224656 17064858</gtr:impact><gtr:outcomeId>BECB8F52244-1</gtr:outcomeId><gtr:partnerContribution>We have a joint programme of work including a joint LLR Programme grant</gtr:partnerContribution><gtr:piContribution>We provide the majority of the research effort in this collaborative programme. We study the molecular and cellular basis of leukaemia using patient samples and mouse models that we are generating.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Stanford University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Development of novel therapeutic anti-leuakemia stem cell antibodies</gtr:description><gtr:id>7A7E684C-64A5-4C7A-9D5B-6FACA7FDF6A3</gtr:id><gtr:impact>Grants 2009 &amp;pound;2.2 M MRC Disease Team Award Publications (PubMed ID numbers below): 19664981 19546437 19644143</gtr:impact><gtr:outcomeId>B7E2966F68D-1</gtr:outcomeId><gtr:partnerContribution>It has provided access to novel technologies and unpublished dataAccess to novel therapies. Access to patient samples. Access to laboratory collaborations. Acquisition of biological samples and clinical data. Acquisition of biological samples and clinical data</gtr:partnerContribution><gtr:piContribution>We lead the UK component of this transatlantic collaboration. The basic science and translational studies are driven from Oxford.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Haematology</gtr:department><gtr:description>Development of novel therapeutic anti-leuakemia stem cell antibodies</gtr:description><gtr:id>F9BA0135-1641-474B-BD11-9CB03811978A</gtr:id><gtr:impact>Grants 2009 &amp;pound;2.2 M MRC Disease Team Award Publications (PubMed ID numbers below): 19664981 19546437 19644143</gtr:impact><gtr:outcomeId>B7E2966F68D-3</gtr:outcomeId><gtr:partnerContribution>It has provided access to novel technologies and unpublished dataAccess to novel therapies. Access to patient samples. Access to laboratory collaborations. Acquisition of biological samples and clinical data. Acquisition of biological samples and clinical data</gtr:partnerContribution><gtr:piContribution>We lead the UK component of this transatlantic collaboration. The basic science and translational studies are driven from Oxford.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Science Week</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>9B86D5C0-0657-40B9-B981-56B167AE9B35</gtr:id><gtr:impact>Oxford Science Week is held annually to an audience of scientists and the general public.

Good feedback from schools</gtr:impact><gtr:outcomeId>67D8B48106B</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Student Presentations</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>854EB905-EFDD-41AB-8564-38E15769E870</gtr:id><gtr:impact>Final year students present their work to the members of the Weatherall Institute of Molecular Medicine. This presentation day is held annually.

Improved student training.</gtr:impact><gtr:outcomeId>F30E22D719D</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>174000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Celgene PhD Studentship</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>Celgene</gtr:fundingOrg><gtr:id>C1F361FC-3727-4339-B154-01643D65E1F3</gtr:id><gtr:outcomeId>F10F7B4B6040</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2009 Disease Team Award</gtr:description><gtr:end>2014-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>CEEAFE6B-468B-4D94-A78B-B49667579A86</gtr:id><gtr:outcomeId>55756B3EA280</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>520000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Molecular Haematology Unit Award</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>7D93DC5E-5100-4D73-B8EC-C805AFAD9F23</gtr:id><gtr:outcomeId>gtvjc4DAy2Y</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1034000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Leukaemia Research Specialist Programme Grant 2008</gtr:description><gtr:end>2013-07-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>472B9831-018D-4CF5-BFDF-BF4D83E1FCAC</gtr:id><gtr:outcomeId>BB2957F94F50</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>10C021B0-0AEF-4219-BAFF-A062BE008412</gtr:id><gtr:title>GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b244db03523acfcca3e96a5f37df371"><gtr:id>8b244db03523acfcca3e96a5f37df371</gtr:id><gtr:otherNames>Roberts I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_15590_20_24021668</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7B33F89-62B8-4015-B767-B9AB2184BCA5</gtr:id><gtr:title>Characterization of a megakaryocyte-specific enhancer of the key hemopoietic transcription factor GATA1.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/44c70118aad8ec449e653b7f8a3c11f0"><gtr:id>44c70118aad8ec449e653b7f8a3c11f0</gtr:id><gtr:otherNames>Guyot B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>10C520BB3A8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59FE8553-9ACF-426B-AB87-9544DC9E6E87</gtr:id><gtr:title>Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9fe1d78d9f73909aa0285fb1be6f87e2"><gtr:id>9fe1d78d9f73909aa0285fb1be6f87e2</gtr:id><gtr:otherNames>Mussai F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_15590_20_23733335</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49935967-7707-4AF5-B10E-7C9100A7EAAB</gtr:id><gtr:title>The impact of trisomy 21 on early human hematopoiesis.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4f5d0920d73a0a7caca3b42bf26d5a4"><gtr:id>f4f5d0920d73a0a7caca3b42bf26d5a4</gtr:id><gtr:otherNames>Roy A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn><gtr:outcomeId>pm_15590_20_23343767</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA6501D4-D704-475B-8B3E-87B5849FAAA3</gtr:id><gtr:title>Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update.</gtr:title><gtr:parentPublicationTitle>Current hematologic malignancy reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ffacc5d7a7ea76b73eb0cef1a95f511"><gtr:id>6ffacc5d7a7ea76b73eb0cef1a95f511</gtr:id><gtr:otherNames>Bhatnagar N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1558-8211</gtr:issn><gtr:outcomeId>58a6cd728ecd58.53272899</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>002045C6-AD0E-4ECF-86EB-A6E48B85C07F</gtr:id><gtr:title>Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00223d0cb2f2c2b62ce0eb3ce2a48d21"><gtr:id>00223d0cb2f2c2b62ce0eb3ce2a48d21</gtr:id><gtr:otherNames>Craddock C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>pm_15590_20_23223186</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06CC5DD0-522A-4874-A16A-77CEC692A3AB</gtr:id><gtr:title>Differences in the chromatin structure and cis-element organization of the human and mouse GATA1 loci: implications for cis-element identification.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b65903b3f1e7fa1d8854448a20196a50"><gtr:id>b65903b3f1e7fa1d8854448a20196a50</gtr:id><gtr:otherNames>Valverde-Garduno V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_15590_10_15265794</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB41E803-33B6-4095-BC11-3BA6E49DBB57</gtr:id><gtr:title>Impact of isolated germline JAK2V617I mutation on human hematopoiesis.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5fb12a98d4056670ebefede87ebda6ba"><gtr:id>5fb12a98d4056670ebefede87ebda6ba</gtr:id><gtr:otherNames>Mead AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_15590_20_23535062</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13261E74-55B6-4C6A-B283-CA8DCF4D993F</gtr:id><gtr:title>Genome-wide identification of TAL1's functional targets: insights into its mechanisms of action in primary erythroid cells.</gtr:title><gtr:parentPublicationTitle>Genome research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7bf1029bbe5b1aff4aa3e3e887a85dbf"><gtr:id>7bf1029bbe5b1aff4aa3e3e887a85dbf</gtr:id><gtr:otherNames>Kassouf MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1088-9051</gtr:issn><gtr:outcomeId>g1bgsc55ak9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63EA2297-424E-473C-94FE-6AF695019FA9</gtr:id><gtr:title>Deletion of the major GATA1 enhancer HS 1 does not affect eosinophil GATA1 expression and eosinophil differentiation.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/44c70118aad8ec449e653b7f8a3c11f0"><gtr:id>44c70118aad8ec449e653b7f8a3c11f0</gtr:id><gtr:otherNames>Guyot B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_15590_10_15016648</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D56D697D-DC23-4227-811F-35630BE6FEC6</gtr:id><gtr:title>Structural basis for LMO2-driven recruitment of the SCL:E47bHLH heterodimer to hematopoietic-specific transcriptional targets.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a017171bc87b2f6382042a9f9a3a08be"><gtr:id>a017171bc87b2f6382042a9f9a3a08be</gtr:id><gtr:otherNames>El Omari K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>pm_15590_20_23831025</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA90FCF1-EE7A-4645-B53F-490195B87883</gtr:id><gtr:title>Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d776866a5dee0d8e2f2f02303fedd07"><gtr:id>0d776866a5dee0d8e2f2f02303fedd07</gtr:id><gtr:otherNames>Eyre T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_15590_20_23175662</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E1349484-9B62-4EB9-ABEB-1CE89CC42684</gtr:id><gtr:title>Lineage-specific combinatorial action of enhancers regulates mouse erythroid Gata1 expression.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c898c712828706075492c628cb10fce"><gtr:id>5c898c712828706075492c628cb10fce</gtr:id><gtr:otherNames>Drissen R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>TohnmM93RcU</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B118C11-731C-43A1-8DDE-1677C3E4CC87</gtr:id><gtr:title>The impact of trisomy 21 on foetal haematopoiesis.</gtr:title><gtr:parentPublicationTitle>Blood cells, molecules &amp; diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b244db03523acfcca3e96a5f37df371"><gtr:id>8b244db03523acfcca3e96a5f37df371</gtr:id><gtr:otherNames>Roberts I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1079-9796</gtr:issn><gtr:outcomeId>pm_15590_20_23932236</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE205913-91EB-48B7-BD2C-10C414E6D202</gtr:id><gtr:title>Clinical and biological implications of driver mutations in myelodysplastic syndromes.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4c954d767ba92727eabc85d0b700988"><gtr:id>c4c954d767ba92727eabc85d0b700988</gtr:id><gtr:otherNames>Papaemmanuil E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_15590_20_24030381</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5DC1F60-3EE8-4CD6-BE2B-9D54217E6D04</gtr:id><gtr:title>Different sequence requirements for expression in erythroid and megakaryocytic cells within a regulatory element upstream of the GATA-1 gene.</gtr:title><gtr:parentPublicationTitle>Development (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c3545a0abfc060e990dc3441ab241c85"><gtr:id>c3545a0abfc060e990dc3441ab241c85</gtr:id><gtr:otherNames>Vyas P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1999-01-01</gtr:date><gtr:issn>0950-1991</gtr:issn><gtr:outcomeId>pm_15590_10_10331989</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A410F30-A307-4A83-BDD1-33D92A2F999C</gtr:id><gtr:title>Uncoupling VEGFA functions in arteriogenesis and hematopoietic stem cell specification.</gtr:title><gtr:parentPublicationTitle>Developmental cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e3074d3fc43b0c44b68d9cfe2dfd095"><gtr:id>1e3074d3fc43b0c44b68d9cfe2dfd095</gtr:id><gtr:otherNames>Leung A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1534-5807</gtr:issn><gtr:outcomeId>pm_15590_20_23318133</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53269276-8815-4574-B822-D31651F37706</gtr:id><gtr:title>FLT3-ITDs instruct a myeloid differentiation and transformation bias in lymphomyeloid multipotent progenitors.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5fb12a98d4056670ebefede87ebda6ba"><gtr:id>5fb12a98d4056670ebefede87ebda6ba</gtr:id><gtr:otherNames>Mead AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>pm_15590_20_23727242</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U137961146</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>939798CA-B6AE-4C12-9DCC-A0F88F84E6F3</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Blood</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>